Month: November 2025

FRONTLINE PLC REPORTS RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025 Frontline plc (the “Company”, “Frontline,” “we,” “us,” or “our”), today reported unaudited results for the three and nine months ended September 30, 2025: HighlightsProfit of $40.3 million, or $0.18 per share for the third quarter of 2025. Adjusted profit of $42.5 million, or $0.19 per share for the third quarter of 2025. Declared a cash dividend of $0.19 per share for the third quarter of 2025. Reported revenues of $432.7 million for the third quarter of 2025. Achieved average daily spot time charter equivalent earnings (“TCEs”)1 for VLCCs, Suezmax tankers and LR2/Aframax tankers in the third quarter of $34,300, $35,100 and $31,400 per day, respectively. Converted seven existing credit facilities with aggregate outstanding term loan balances of...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR 21 NOVEMBER 2025 RICHEMONT’S 2025 INTERIM REPORT NOW AVAILABLE ONLINE Richemont announces the publication of its interim report and accounts for the six-month period ended 30 September 2025. The report is available for download from the Richemont website at: www.richemont.com/investors/results-reports-presentations/ The interim report reflects the information contained in the Richemont results announcement issued on 14 November 2025 as well as the unaudited condensed interim consolidated financial statements posted on the Group’s website the same day. In accordance with stock exchange regulations in Switzerland and South Africa, Richemont no longer prints its interim report. About Richemont At Richemont, we craft the future. Our unique portfolio includes prestigious Maisons distinguished by their...

Bekaert announces the next tranche of its Share Buyback Program Bekaert announces that it will start the next tranche of its buyback program on 21 November 2025, for a total consideration of up to € 25 million. It is intended that, subject to market conditions, this tranche will be completed prior to the release of the full year 2025 results, scheduled for 26 February 2026. During this period, Bekaert will regularly publish press releases with updates on the progress made, as required by law. This information will also be available on the investor relations pages of our website. As announced previously, all shares bought as part of the Program will be cancelled.  Attachmentp251121E – Bekaert announces the next tranche of its Share Buyback Program

These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnership Company is in advanced stages to finalize a strategic transaction with a potential partner, and it remains on track to complete the transaction by year end These agreements ensure BioAtla can maintain operational momentum while completing that processSAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into Pre-paid Advance Agreements with an affiliate of Yorkville Advisors Global (Yorkville) and funds managed by of Anson Advisors Inc. to provide an aggregate $7.5 million advance...

WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the pricing of its underwritten public offering of 46,091,739 shares of common stock and pre-funded warrants to purchase 22,873,779 shares of common stock. The shares of common stock are being sold at an offering price of $1.45 per share, and the pre-funded warrants are being sold at an offering price of $1.449 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. In addition, Inhibikase has granted the underwriters a 30-day option to purchase up to an additional...

COLUMBUS, Ohio, Nov. 20, 2025 (GLOBE NEWSWIRE) — Bread Financial Holdings, Inc. (NYSE: BFH) (“Bread Financial” or the “Company”) announced today the pricing of its previously announced underwritten public offering of depositary shares (the “Depositary Shares”), each representing a 1/40th interest in a share of its Non-Cumulative Perpetual Preferred Stock, Series A, par value $0.01 per share (the “Series A Preferred Stock”), with a liquidation preference of $25 per Depositary Share (equivalent to $1,000 per share of Series A Preferred Stock). The Company expects to apply to list the Depositary Shares on The New York Stock Exchange. The closing of the offering of the Depositary Shares is expected to occur on November 25, 2025, subject to the satisfaction of customary closing conditions, and is expected to result in approximately...

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program The ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class team VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) — NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that its subsidiary Visara, Inc. (Visara) has appointed Cadmus...